Cargando…
Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma
BACKGROUND: Synovial sarcoma is a high-grade malignant tumor of soft tissue, characterized by the specific chromosomal translocation t(X;18), and its resultant SYT-SSX fusion gene. Despite intensive multimodality therapy, the majority of metastatic or relapsed diseases still remain incurable, thus s...
Autores principales: | Kawaguchi, Satoshi, Wada, Takuro, Ida, Kazunori, Sato, Yuriko, Nagoya, Satoshi, Tsukahara, Tomohide, Kimura, Sigeharu, Sahara, Hiroeki, Ikeda, Hideyuki, Shimozawa, Kumiko, Asanuma, Hiroko, Torigoe, Toshihiko, Hiraga, Hiroaki, Ishii, Takeshi, Tatezaki, Shin-ichiro, Sato, Noriyuki, Yamashita, Toshihiko |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC545052/ https://www.ncbi.nlm.nih.gov/pubmed/15647119 http://dx.doi.org/10.1186/1479-5876-3-1 |
Ejemplares similares
-
SYT-SSX fusion genes and prognosis in synovial sarcoma
por: Mezzelani, A, et al.
Publicado: (2001) -
HLA-A*0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor
por: Tsukahara, Tomohide, et al.
Publicado: (2009) -
A quest for therapeutic antigens in bone and soft tissue sarcoma
por: Kawaguchi, Satoshi, et al.
Publicado: (2005) -
The Synovial Sarcoma-Associated SYT-SSX2 Oncogene Antagonizes the Polycomb Complex Protein Bmi1
por: Barco, Roy, et al.
Publicado: (2009) -
Genome-wide recruitment to Polycomb-modified chromatin and activity regulation of the synovial sarcoma oncogene SYT-SSX2
por: Garcia, Christina B, et al.
Publicado: (2012)